Portfolio company Terns Pharmaceuticals was acquired by Merck for $6.7B.
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases, including oncology and obesity
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases, including oncology and obesity.